No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19

https://doi.org/10.1007/s42770-020-00395-x

This prospective study comprised consecutive viral load measurements in patients with COVID-19 hospitalized with a moderate illness. Patients received 400 mg of HCQ every 12 h for 10 days according to the medical decision. Nasal swab samples were collected from patients during early, intermediary, and final clinical stage of COVID-19. A total of 155 samples were collected from 66 patients with COVID-19 (60% female), with a median age of 58 years. The viral load between studied groups, assumed as a semiquantitative measure of cycle threshold (Ct) values, presented no significant difference within the three consecutive measures (DeltaCt) (p > 0.05). We also analyzed the DeltaCt viral load at different intervals of sample collection (Deltat < 7; 7-12; and > 12 days) without significant differences at any DeltaCt (p > 0.05). In this study, we did not observe any change in viral load reduction in vivo with the use of HCQ.

Tags: